This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, B. Articles by Guo, Y. Search for Related Content PubMed PubMed Citation Articles by Li, B. Articles by Guo, Y.

Development of Novel Tetravalent Anti-CD20 Antibodies with Potent Antitumor Activity

¹ International Joint Cancer Institute, Second Military Medical University and ² Shanghai Center for Cell Engineering and Antibody, Shanghai, People's Republic of China

Requests for reprints: Yajun Guo, International Joint Cancer Institute, Second Military Medical University, 800 Xiang Yin Road, Shanghai 200433, People's Republic of China. Phone: 86-21-25070241; Fax: 86-21-25074349; E-mail: yjguo{at}smmu.edu.cn.

Key Words: CD20 • tetravalent • antibody • lymphoma • immunotherapy

Despite the effectiveness of the anti-CD20 monoclonal antibody (mAb) Rituximab (C2B8) in the treatment of B-cell lymphoma, its efficacy remains variable and often modest. It seems likely that a combination of multiple mechanisms, such as complement-dependent cytotoxicity (CDC) and apoptotic signaling, underlies the therapeutic success of anti-CD20 mAbs. Unfortunately, all the current anti-CD20 mAbs effective in CDC are relatively inactive in signaling cell death and vice versa. In this study, we developed two genetically engineered tetravalent antibodies (TetraMcAb) respectively derived from the anti-CD20 mAbs C2B8 and 2F2. TetraMcAbs, with a molecular mass only 25 kDa higher than native divalent antibodies (DiMcAb), were shown not only to be as effective in mediating CDC and antibody-dependent cellular cytotoxicity against B-lymphoma cells as DiMcAbs but also to have antiproliferative and apoptosis-inducing activity markedly superior to that of DiMcAbs. Interestingly, whereas 2F2 and C2B8 were equally effective in inducing cell growth arrest and apoptosis, the functions of their tetravalent versions, 2F2(ScFvHL)₄-Fc and C2B8(ScFvHL)₄-Fc, were significantly different. 2F2(ScFvHL)₄-Fc exhibited exceptionally more potent antiproliferative and apoptosis-inducing activity than that of C2B8(ScFvHL)₄-Fc. Immunotherapeutic studies further showed that 2F2(ScFvHL)₄-Fc was far more effective in prolonging the survival of severe combined immunodeficient mice bearing systemic Daudi or Raji tumors than C2B8, 2F2, and C2B8(ScFvHL)₄-Fc, suggesting that it might be a promising therapeutic agent for B-cell lymphoma. [Cancer Res 2008;68(7):2400–8]

This article has been cited by other articles:

				E. A. Rossi, D. M. Goldenberg, T. M. Cardillo, R. Stein, and C.-H. Chang Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma Blood, June 11, 2009; 113(24): 6161 - 6171. [Abstract] [Full Text] [PDF]

				E. A. Rossi, D. M. Goldenberg, T. M. Cardillo, R. Stein, Y. Wang, and C.-H. Chang Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics Cancer Res., October 15, 2008; 68(20): 8384 - 8392. [Abstract] [Full Text] [PDF]